title: Long versus standard initial steroid therapy for children with the nephrotic syndromeA report from the Southwest Pediatric Nephrology Study Group.
abstract: A retrospective cohort study was conducted by the Southwest Pediatric Nephrology Study Group (SPNSG) to address whether a longer initial course of corticosteroids in patients with idiopathic nephrotic syndrome (INS) provides superior protection against relapse without increased adverse effects. In order to be included in the evaluation, patients with INS must have responded to an initial steroid course, either standard or long regimen as defined here, and completed at least 1 year of follow-up. The standard regimen consisted of prednisone 2.0+/-0.3 mg/kg per day or 60+/-10 mg/m(2) per day for 28+/-4 days, followed by alternate-day prednisone for 4-12 weeks. The long regimen consisted of daily prednisone 2.0+/-0.3 mg/kg per day or 60+/-10 mg/m(2) per day for 42+/-6 days, followed by alternate-day prednisone for 6-14 weeks. The primary outcome measure was relapse of NS within 12 months of discontinuing the initial course of prednisone. There were 151 children who met the criteria for the study; 82 received the standard regimen and 69 the long regimen. The two groups did not differ in age, race, blood pressure, serum albumin, or serum cholesterol prior to the initial steroid course. The cumulative prednisone dose was 49% higher in the long regimen group than in the standard regimen group. Relapse within 12 months was reported in 72.5% of patients who received the long regimen versus 84.1% of those who received the standard regimen. The odds ratio for relapse within 12 months was 0.496 (95% confidence interval 0.22, 1.088), long versus standard regimen. This did not reach statistical significance ( chi(2)=3.058, P=0.08). The odds ratio of experiencing at least one side effect was 3.76, long relative to standard regimen ( n=133, P<0.001). Our data suggest that prolongation of the steroid treatment for the initial episode of steroid-sensitive NS may have a beneficial effect, but at the cost of increased side effects. However, definitive conclusions are limited by the retrospective design of the study and the number of patients. This may have caused failure to achieve statistical significance on the basis of a type II error.
authors.affiliation: University of Rochester, Rochester, New York, USA.
authors.forename: Marc B
authors.initials: MB
authors.lastname: Lande
authors.forename: Christina
authors.initials: C
authors.lastname: Gullion
authors.forename: Ronald J
authors.initials: RJ
authors.lastname: Hogg
authors.forename: Bernard
authors.initials: B
authors.lastname: Gauthier
authors.forename: Binod
authors.initials: B
authors.lastname: Shah
authors.forename: Mary B
authors.initials: MB
authors.lastname: Leonard
authors.forename: Melvin
authors.initials: M
authors.lastname: Bonilla-Felix
authors.forename: Martin
authors.initials: M
authors.lastname: Nash
authors.forename: Shane
authors.initials: S
authors.lastname: Roy
authors.forename: C Frederic
authors.initials: CF
authors.lastname: Strife
authors.forename: Gerald
authors.initials: G
authors.lastname: Arbus
mesh_terms: D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D002170:Canada; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D007223:Infant; D008297:Male; D009404:Nephrotic Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012189:Retrospective Studies; D018570:Risk Assessment; D013256:Steroids / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D014481:United States
chemical_list: D000893:Anti-Inflammatory Agents; D013256:Steroids; D011241:Prednisone